Gough K, Maddison B, Shikotra A, Moiseeva E, Yang W, Jarvis S, et al. Evidence for a novel Kit adhesion domain mediating human mast cell adhesion to structural airway cells. Respir Res. 2015;16:86 pubmed publisher

Moiseeva E, Straatman K, Leyland M, Bradding P. CADM1 controls actin cytoskeleton assembly and regulates extracellular matrix adhesion in human mast cells. PLoS ONE. 2014;9:e85980 pubmed publisher

McLean S, Gana-Weisz M, Hartzoulakis B, Frow R, Whelan J, Selwood D, et al. Imatinib binding and cKIT inhibition is abrogated by the cKIT kinase domain I missense mutation Val654Ala. Mol Cancer Ther. 2005;4:2008-15 pubmed

Growney J, Clark J, Adelsperger J, Stone R, Fabbro D, Griffin J, et al. Activation mutations of human c-KIT resistant to imatinib mesylate are sensitive to the tyrosine kinase inhibitor PKC412. Blood. 2005;106:721-4 pubmed

Fernandez A, Sanguino A, Peng Z, Ozturk E, Chen J, Crespo A, et al. An anticancer C-Kit kinase inhibitor is reengineered to make it more active and less cardiotoxic. J Clin Invest. 2007;117:4044-54 pubmed

Almeida M, Harran M, Bimpaki E, Hsiao H, Horvath A, Cheadle C, et al. Integrated genomic analysis of nodular tissue in macronodular adrenocortical hyperplasia: progression of tumorigenesis in a disorder associated with multiple benign lesions. J Clin Endocrinol Metab. 2011;96:E728-38 pubmed publisher

Huang X, Schwind S, Yu B, Santhanam R, Wang H, Hoellerbauer P, et al. Targeted delivery of microRNA-29b by transferrin-conjugated anionic lipopolyplex nanoparticles: a novel therapeutic strategy in acute myeloid leukemia. Clin Cancer Res. 2013;19:2355-67 pubmed publisher